Earnings summaries and quarterly performance for GENELUX.
Executive leadership at GENELUX.
Thomas Zindrick
Detailed
President, Chief Executive Officer and Chairman
CEO
EG
Eric Groen
Detailed
General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
JC
Joseph Cappello
Detailed
Chief Technical Officer
MP
Matthew Pulisic
Detailed
Chief Financial Officer
PS
Paul Scigalla
Detailed
Chief Medical Officer
RS
Ralph Smalling
Detailed
Head of Regulatory
TY
Tony Yu
Detailed
Senior Vice President, Clinical Development
Board of directors at GENELUX.
Research analysts covering GENELUX.
Recent press releases and 8-K filings for GNLX.
Genelux Corporation Prices Public Offering of Common Stock
GNLX
New Projects/Investments
- Genelux Corporation priced an underwritten public offering of 6,666,667 shares of its common stock at $3.00 per share.
- The offering is expected to generate approximately $20.0 million in gross proceeds for Genelux.
- The company granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of common stock.
- The net proceeds are expected to be used for general corporate purposes, including research and development expenses, clinical trial expenses, capital expenditures, and working capital.
- The offering is anticipated to close on or about January 9, 2026.
Jan 8, 2026, 10:09 PM
Genelux Corporation Announces Pricing of Public Offering
GNLX
New Projects/Investments
- Genelux Corporation priced an underwritten public offering of 6,666,667 shares of its common stock at $3.00 per share.
- The offering is expected to generate approximately $20.0 million in gross proceeds for Genelux.
- The net proceeds are anticipated to be used for general corporate purposes, including research and development expenses, clinical trial expenses, capital expenditures, and working capital.
- The offering is expected to close on or about January 9, 2026.
Jan 8, 2026, 2:13 PM
Genelux Corporation Announces Proposed Public Offering
GNLX
- Genelux Corporation (GNLX) has commenced a proposed underwritten public offering of its common stock.
- The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering.
- All shares are being offered by Genelux, with Lucid Capital Markets acting as the sole book-running manager.
- The proposed offering is subject to market and other customary closing conditions.
Jan 7, 2026, 9:01 PM
Genelux Reports Encouraging Interim Data from Lung Cancer Trials
GNLX
New Projects/Investments
- Genelux Corporation announced encouraging interim results from two ongoing trials, Phase 1b/2 SCLC and Phase 2 VIRO-25, evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) after failure of prior platinum-based regimens.
- In the Phase 1b/2 SCLC trial, as of December 23, 2025, 9 evaluable patients showed an Overall Response Rate (ORR) of 33% (3/9 patients), with a 67% (2/3) ORR in the highest dose cohort, and a Disease Control Rate (DCR) of 67% (6/9 patients).
- For the Phase 2 VIRO-25 trial in NSCLC, as of December 31, 2025, 5 evaluable patients demonstrated a DCR of 60% (3/5 patients), with tumor size changes among the three DCR patients ranging from 8.9% to -22.7%.
- Olvi-Vec was generally well tolerated in both lung cancer trials.
- The company anticipates additional systemic lung cancer data readouts throughout 2026 and topline data from the Phase 3 ovarian cancer trial (OnPrime/GOG-3076) in the second half of 2026.
Jan 5, 2026, 1:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more